Adagene Presents Interim Monotherapy Data at ESMO 2022 Showi

Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

GlobeNewswire

September 10, 2022



- Best-in-class profile demonstrated with repeat dosing across dose levels - The poster, titled “Phase 1 Results Demonstrate Highly Differentiated Safety and PK...

Related Keywords

Monash , South Australia , Australia , Japan , United States , Paris , France General , France , Singapore , Suzhou , Jiangsu , China , Gary Richardson , Asia Pacific , Knoefler Adagene , Adagene Inc , Linkedin , Monash University , Twitter , Cabrini Health Research , Nasdaq , Oncology Research , Exchange Commission , European Union , Dynamic Precision Library , European Society For Medical Oncology , Compelling Safety , Anti Tumor Activity , European Society , Medical Oncology , Demonstrate Highly Differentiated Safety , Advanced Solid Tumors , Cold Tumors , Neil Beauglehall Endowed Chair , Medical Oncology Research , Media Contact , Ami Knoefler Adagene ,